AUM LIFETECH INC
FOXP3-targeting therapeutic to deplete or modulate T-regulatory cells in lung cancer
- Sector
- Biotech
- Headquarters
- Philadelphia, PA
- Total capital
- $2.1M
- Federal grants
- $2M
- 5 awards · 2020–2022
- Rank in peer group#299 of 326
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $80K
- 6 awards · Agriculture
- Rank in Biotech#338 of 4373
- Granted patents
- 4
- 6 pending · first 2021
- Rank in peer group#35 of 326
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Evaluation of lead FANA oligos targeting FOXP3, with and without anti-PD-1 mAb, as an approach for cancer immunotherapy$400K
- Federal grantHealth and Human S · Phase I · Evaluation of lead FANA oligos targeting FOXP3, with and without anti-PD-1 mAb, as an approach for cancer immunotherapy$400K
- Federal grantHealth and Human S · Phase I · Evaluation of Self-delivering FANA Antisense Oligonucleotide Lead Compounds for HIV Therapy$300K
- Federal grantHealth and Human S · Phase I · Evaluation of Self-delivering FANA Antisense Oligonucleotide Lead Compounds for HIV Therapy$600K
- Federal grantHealth and Human S · Phase I · Evaluation of Self-delivering FANA Antisense Oligonucleotide Lead Compounds for HIV Therapy$300K
- Federal contractAgriculture · Aum Silence Aum-sil-a$20K
- Federal contractAgriculture · Controls$5K
Show 4 earlier federal awards
- Federal contractAgriculture · Igf::ot::igf Synthesis Of Fana Molecules 75-100 Nmoles (quote AUM-XV-190)$15K
- Federal contractAgriculture · Igf::ot::igf Aum Sii A Rpc$17K
- Federal contractAgriculture · Igf::ot::igf 58 Fana Antisense Olig Onucleotides (lyophilized)$13K
- Federal contractAgriculture · Aum Life Tech For 50 Fana Oligonucleotides$10K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#35 · top 11%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 4 granted of 10- PendingTargeted Control Of Weeds And Invasive Plants By Delivery Of 2'FANA Anti-sense OligonucleotidesUSPTOApplication 18841641
- PendingUse Of Fana Antisense Oligonucleotides For The Prevention And Management Of Huanglongbing And Zebra Chip DiseasesUSPTOApplication 18021884
- Granted2'F-ANA-LET7 Mediated Utrophin Upregulation For Dmd TherapyUSPTOUS 12,104,152
Show all 10 patent records
- Targeted Control Of Weeds And Invasive Plants By Delivery Of 2'FANA Anti-sense OligonucleotidesJul 3, 2025 · Application 18841641Pending
- Use Of Fana Antisense Oligonucleotides For The Prevention And Management Of Huanglongbing And Zebra Chip DiseasesJan 23, 2025 · Application 18021884Pending
- 2'F-ANA-LET7 Mediated Utrophin Upregulation For Dmd TherapyOct 1, 2024 · US 12,104,152Granted
- Targeted Control Of Pests And Pathogens By Plant Delivery Of 2'F-ANA-OLIGONUCLEOTIDESApr 2, 2024 · US 11,946,058Granted
- Modulation Of Micrornas Against Myotonic Dystrophy Type 1 And Antagonists Of Micrornas ThereforMay 5, 2022 · Application 17525672Pending
- Targeted Control Of Pests And Pathogens By Plant Delivery Of 2'F-ANA-OLIGONUCLEOTIDESFeb 22, 2022 · US 11,254,945Granted
- Modulation Of Micrornas Against Myotonic Dystrophy Type 1 And Antagonists Of Micrornas ThereforDec 21, 2021 · US 11,202,794Granted
- Targeted Control of Weeds and Invasive Plants by Delivery of FANA Anti-Sense OligonucleotidesApplication 63315211Pending
- 2'F-ANA-LET7 Mediated Utrophin Upregulation For Dmd TherapyApplication PCTUS2019022826Pending
- 2'F-ANA-LET7 Mediated Utrophin Upregulation For Dmd TherapyApplication 62645170Pending
Related companies, and why
- Bellbrook Labs, LLCSimilar federal contract value in Biotech · $90K in contracts
- FINA BIOSOLUTIONS LLCSimilar federal contract value in Biotech · $83K in contracts
- Celularity IncSimilar federal contract value in Biotech · $80K in contracts
- PRIMETIME LIFE SCIENCES, LLCSimilar federal contract value in Biotech · $79K in contracts
- Nexome Genomics Inc.Similar federal contract value in Biotech · $78K in contracts
- ORA BIOMEDICAL, INC.Similar federal contract value in Biotech · $75K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .